Pay in 4 interest-free payments of $6.55 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
A study published in the Journal of the American Academy of Dermatology compared more than 1 million GLP-1 users with patients taking metformin, a common diabetes drug that is not associated with the same dramatic weight loss
As a clinically researched immune activator* supported by 30 published studies, including 15 human trials, IMMUSE is a postbiotic that delivers a new, breakthrough approach to broad-range immune support*
These findings underscore the variability in weight management outcomes among patients post-bariatric surgery and highlight the potential role of GLP-1RAs in addressing WR in this population
Appetite effects versus weight effects An important distinction from the research: appetite reduction precedes weight loss
The titration plan is always individualized
